Lake Bluff, IL, United States of America

Seble H Wagaw

This inventor holds 11 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Abbvie Inc., Enanta Pharmaceuticals, Inc.. Active years: 2012-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Seble H Wagaw. Retrieved from https://idiyas.com/inventor/seble-h-wagaw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 6)

% Patents Active = 63.6

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 16.4

ph-index = 3

Forward Citations = 38(Granted Patents)

Location History:

Evanston, IL (US) (2012 - 2016)
Lake Bluff, IL (US) (2017 - 2018)

Company Filing History:

Enanta Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2012-2018

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10039754 - Anti-viral compounds (2018-08-07),

2. 10028937 - Anti-viral compounds (2018-07-24),

3. 9586978 - Anti-viral compounds (2017-03-07),

4. 9469673 - Crystaline forms of HCV inhibitor (2016-10-18),

5. 9309279 - Macrocyclic hepatitis C serine protease inhibitors (2016-04-12),

6. 9260411 - Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile (2016-02-16),

7. 9006387 - Anti-viral compounds (2015-04-14),

8. 8937150 - Anti-viral compounds (2015-01-20),

9. 8921514 - Anti-viral compounds (2014-12-30),

10. 8691938 - Anti-viral compounds (2014-04-08),

11. 8193346 - Process for making macrocyclic oximyl hepatitis C protease inhibitors (2012-06-05),

Title: Innovations by Seble H Wagaw in Antiviral Research

Introduction

Seble H Wagaw is an accomplished inventor based in Lake Bluff, IL, known for his significant contributions to the field of antiviral research. With a total of 11 patents to his name, Wagaw has made remarkable advancements, particularly in the fight against Hepatitis C virus (HCV).

Latest Patents

Among his latest innovations, Wagaw has developed compounds that are effective in inhibiting the replication of Hepatitis C virus (HCV). These patents describe a range of compounds along with processes for their manufacture, compositions that comprise these compounds, and methods for utilizing them in the treatment of HCV infection.

Career Highlights

Wagaw has carved out an influential career, working for notable companies such as AbbVie Inc. and Enanta Pharmaceuticals, Inc. His work at these institutions has played a crucial role in the development of antiviral therapies.

Collaborations

Throughout his career, Wagaw has collaborated with esteemed colleagues like David A DeGoey and Warren M Kati, further enriching his research and innovation efforts in the industry.

Conclusion

Seble H Wagaw’s contributions to antiviral research, particularly in the advancement of Hepatitis C treatments, highlight his commitment to innovation in the medical field. His numerous patents not only showcase his expertise but also hold promise for improving patient outcomes in the future.

Profile summary based on public USPTO records.